Ceribell, a seizure diagnostics platform, announced Wednesday that it has raised a $50 million extension to its previously announced Series C round. The new funding round, led by Ally Bridge Group, brings the round’s total to $103 million. Ceribell plans to use the funding for commercial expansion across departments and intensive care units.
Ceribell’s platform uses a cloud-linked, portable EEG device to analyze brain waves in order to identify whether patients are at risk of having seizures or other neurological conditions. This speeds up access to care, helping patients get diagnosed quicker and easier.
“Based on our progress to date, it is clear that the Ceribell Rapid EEG system is improving the quality of care seizure patients receive in the hospital,” Ceribell co-founder and CEO Jane Chao said in a statement. “We look forward to continuing to bring this novel technology to more ICUs and Emergency Departments, as well as developing diagnostic and monitoring solutions for additional neurological indications impacting the lives of critically ill patients.”
Earlier this month, Ceribell received the FDA’s Breakthrough Device Designation for its delirium indicator. The company is also currently working on expanding its platform’s machine learning capabilities to help diagnose additional neurological conditions beyond seizures.
Ceribell is also expanding its team, currently hiring 23 positions across multiple departments.
